Charles River Laboratories International (NYSE:CRL) Price Target Raised to $227.00

Charles River Laboratories International (NYSE:CRL) had its price objective upped by TD Cowen from $203.00 to $227.00 in a research report sent to investors on Monday,Benzinga reports. TD Cowen currently has a hold rating on the medical research company’s stock.

CRL has been the topic of a number of other research reports. The Goldman Sachs Group lowered their target price on shares of Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating on the stock in a research note on Thursday, August 8th. CLSA upgraded Charles River Laboratories International from an “underperform” rating to a “hold” rating and set a $205.00 price objective on the stock in a research note on Thursday, November 7th. UBS Group raised their target price on Charles River Laboratories International from $240.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Barclays lowered their price target on Charles River Laboratories International from $230.00 to $210.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 8th. Finally, Citigroup cut Charles River Laboratories International from a “neutral” rating to a “sell” rating and cut their price objective for the company from $215.00 to $175.00 in a report on Tuesday, October 1st. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $217.54.

Charles River Laboratories International Stock Down 4.4 %

CRL stock opened at $206.54 on Monday. The business’s 50-day simple moving average is $195.14 and its 200 day simple moving average is $207.90. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. The company has a market cap of $10.56 billion, a PE ratio of 25.85, a price-to-earnings-growth ratio of 5.57 and a beta of 1.38. Charles River Laboratories International has a twelve month low of $174.92 and a twelve month high of $275.00.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. The business had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. Charles River Laboratories International’s quarterly revenue was down 1.6% on a year-over-year basis. During the same period in the previous year, the business posted $2.72 earnings per share. On average, research analysts anticipate that Charles River Laboratories International will post 10.18 earnings per share for the current year.

Charles River Laboratories International announced that its board has authorized a stock repurchase plan on Wednesday, August 7th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the medical research company to reacquire up to 9.6% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s management believes its stock is undervalued.

Insiders Place Their Bets

In other news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the sale, the director now directly owns 12,386 shares of the company’s stock, valued at $2,676,862.32. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 1.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Boston Trust Walden Corp lifted its stake in shares of Charles River Laboratories International by 2.8% during the second quarter. Boston Trust Walden Corp now owns 200,314 shares of the medical research company’s stock valued at $41,381,000 after acquiring an additional 5,375 shares during the period. State Board of Administration of Florida Retirement System lifted its position in Charles River Laboratories International by 5.1% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 56,840 shares of the medical research company’s stock valued at $15,401,000 after purchasing an additional 2,739 shares during the period. Natixis bought a new position in shares of Charles River Laboratories International in the 1st quarter valued at about $1,058,000. Tidal Investments LLC grew its position in shares of Charles River Laboratories International by 99.8% during the 1st quarter. Tidal Investments LLC now owns 5,297 shares of the medical research company’s stock worth $1,435,000 after buying an additional 2,646 shares during the period. Finally, Epoch Investment Partners Inc. raised its stake in shares of Charles River Laboratories International by 2,733.4% during the first quarter. Epoch Investment Partners Inc. now owns 247,501 shares of the medical research company’s stock worth $67,060,000 after buying an additional 238,766 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).